CoChat

Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Importance: Predicting undesirable outcomes following anti-VEGF initiation in macular oedema is critical for effective clinical decision-making and optimised care. Objective: To estimate the time to undesirable events in diabetic macular oedema (DMO), central and branch vein occlusions (CRVO and BRVO) after appropriate loading doses with either ranibizumab or aflibercept and identified baseline predictors of negative outcome. Design, setting, participants: A retrospective cohort study of 3277 patients ( N = 2107 in DMO, N = 413 in CRVO and N = 757 in BRVO) collected over a 10-year period, in a large UK tertiary centre. Only one eye was included per patient. Inclusion criteria pre-specified a minimum of two clinic visits with one being at least 6 months post treatment. Main outcome and measures: The main outcome measure was absence of visual acuity (VA) improvement due to macular oedema failure of anti-VEGF therapy (defined as VA gain <5 ETDRS letters and CST increase of 50 µm or CST > 325 µm) modelled using time-event analyzes of appropriately loaded patients. Secondary outcomes included survival curves by individual condition (DMO, CRVO, BRVO) and factors associated with negative outcomes. Results: After starting anti-VEGF , there was a 50% chance of undesirable outcomes at 2.3, 5.24 and 6.16 years for DMO, CRVO and BRVO, respectively. Cox proportional hazards modelling identified presenting age, intraretinal (IRF) volume, presence of DMO and VA as predictors of negative outcomes, whilst South East Asian ethnicity conferred an independent protective effect. Conclusion: Real-world data suggest that undesirable events following anti-VEGF injections is likely to in 50% of patients by the third year of treatment in spite of appropriate loading. The definition of undesirable treatment events captured nearly all patients who were escalated to another therapy, but this proportion represented a small percentage of our definition of failed response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41433-024-03529-9

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Macular oedema features. a Automatic segmentation of macular oedema features. Exemplar model output on a full OCT volume for a given eye macular oedema. colour fundus photo (left panel) with en-face projection of OCT B-scans. A single B-scan (indicated with a green line) shown without (middle panel) and with (right panel) segmentation overlay for intraretinal fluid (blue) and subretinal fluid (orange). Volume in nanolitres is the sum of all voxels with a given feature present multiplied by voxel volume. Fovea and retinal sublayers inner limiting membrane and Bruch’s membrane were segmented using the Topcon Advanced Boundary Segmentation Tool (TABS) version 1.6.2.6, software. Central subfoveal thickness in microns was calculated as mean total retinal thickness (inner limiting membrane to Bruch’s membrane) within a 1 mm diameter circle centred on the fovea. Mean absolute values and change from baseline of b visual acuity measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters and c central subfoveal thickness (CST; µm) following initiation of anti-VEGF in patients with diabetic macular oedema (DMO; yellow), central retinal vein occlusion (CRVO; red) and branch retinal vein occlusion (BRVO; red) up to 5 years. Each timepoint allowed a margin of 60 days. Error bars signify standard deviation.
Fig. 1 Macular oedema features. a Automatic segmentation of macular oedema features. Exemplar model output on a full OCT volume for a given eye macular oedema. colour fundus photo (left panel) with en-face projection of OCT B-scans. A single B-scan (indicated with a green line) shown without (middle panel) and with (right panel) segmentation overlay for intraretinal fluid (blue) and subretinal fluid (orange). Volume in nanolitres is the sum of all voxels with a given feature present multiplied by voxel volume. Fovea and retinal sublayers inner limiting membrane and Bruch’s membrane were segmented using the Topcon Advanced Boundary Segmentation Tool (TABS) version 1.6.2.6, software. Central subfoveal thickness in microns was calculated as mean total retinal thickness (inner limiting membrane to Bruch’s membrane) within a 1 mm diameter circle centred on the fovea. Mean absolute values and change from baseline of b visual acuity measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters and c central subfoveal thickness (CST; µm) following initiation of anti-VEGF in patients with diabetic macular oedema (DMO; yellow), central retinal vein occlusion (CRVO; red) and branch retinal vein occlusion (BRVO; red) up to 5 years. Each timepoint allowed a margin of 60 days. Error bars signify standard deviation.CC BY · PubMed Central
Fig. 2 Time to treatment outcomes. a Probability of an undesired treatment outcome (absence of VA improvement or VA-loss attributable to macular oedema) following initiation of anti-VEGF. Kaplan–Meier modelling was carried out to estimate time to treatment failure (one of either: visual acuity (VA) gain less than 5 early treatment diabetic retinopathy study (ETDRS) letters with central subfoveal thickness (CST) 325 µm or more at 2 consecutive visits; VA loss of 10 ETDRS letters and CST increase of 50 µm; or escalation to steroid therapy) sub-stratified by each of the treatment indications (DMO, green; CRVO, red; BRVO, blue; bottom panel). Remaining numbers at risk shown below graph. b Probability of a positive visual outcome following an undesired treatment outcome. Kaplan–Meier modelling was carried out to estimate time to visual acuity gain of 5 early treatment diabetic retinopathy study (ETDRS) letters or more from baseline (initiation of anti-VEGF) following an undesirable treatment outcome sub-stratified by each of the treatment indications (DMO, green; CRVO, red; BRVO, blue; bottom panel). Data were censored following escalation to intravitreal steroid or cataract surgery.
Fig. 2 Time to treatment outcomes. a Probability of an undesired treatment outcome (absence of VA improvement or VA-loss attributable to macular oedema) following initiation of anti-VEGF. Kaplan–Meier modelling was carried out to estimate time to treatment failure (one of either: visual acuity (VA) gain less than 5 early treatment diabetic retinopathy study (ETDRS) letters with central subfoveal thickness (CST) 325 µm or more at 2 consecutive visits; VA loss of 10 ETDRS letters and CST increase of 50 µm; or escalation to steroid therapy) sub-stratified by each of the treatment indications (DMO, green; CRVO, red; BRVO, blue; bottom panel). Remaining numbers at risk shown below graph. b Probability of a positive visual outcome following an undesired treatment outcome. Kaplan–Meier modelling was carried out to estimate time to visual acuity gain of 5 early treatment diabetic retinopathy study (ETDRS) letters or more from baseline (initiation of anti-VEGF) following an undesirable treatment outcome sub-stratified by each of the treatment indications (DMO, green; CRVO, red; BRVO, blue; bottom panel). Data were censored following escalation to intravitreal steroid or cataract surgery.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Metadata

Authors
Fu, D. J., Mishra, A. V., Quek, C., Balaskas, K., Pontikos, N., Sim, D., Sivaprasad, S., & Faes, L.
Affiliations
  • Moorfields Eye Hospital NHS Foundation Trust (GB)
  • National University of Singapore (SG)
  • Roche (United States) (US)
Corresponding author
Fu, Dun Jack
Venue
Eye
Published
2024-12-10
Volume
39
Issue
5
Pages
977-985
ISSN
  • 0078-5334 (ISSN-L)
  • 0950-222X
  • 1476-5454
OpenAlex
W4405225188
Cited by
14
References
34
Citations by year
2026: 11 · 2025: 3
FWCI
5.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Eye (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
AbbVie (SIMD1004)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
anti-VEGF therapy, treatment failure, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, ranibizumab, aflibercept, visual acuity loss, macular thickness, predictors of treatment failure, real-world outcomes
MeSH terms
Ranibizumab, Aged, Diabetic Retinopathy, Female, Humans, Macular Edema, Male, Middle Aged, Recombinant Fusion Proteins, Retinal Vein Occlusion, Retrospective Studies, Visual Acuity, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data. https://app.cochat.ai/papers/10.1038/s41433-024-03529-9
The paper
Fu, D. J., Mishra, A. V., Quek, C., Balaskas, K., Pontikos, N., Sim, D., Sivaprasad, S., & Faes, L. (2025). Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data. Eye. https://doi.org/10.1038/s41433-024-03529-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.